Entry into a Material Definitive Agreement

Business Context and Reporting Period

Company: JATT II Acquisition Corp. (JATT), a Cayman Islands exempted company and emerging growth company.

Reporting Date: June 29, 2026.

Event: JATT entered into a Business Combination Agreement with Talawar Tx Inc. (the "Company") and Talawar Merger Sub. The transaction involves a merger where JATT will become a wholly-owned subsidiary of the Company. The combined entity intends to list on the Nasdaq Capital Market.

Key Financial Metrics and Transaction Terms

  • PIPE Financing: Agreements signed for the purchase of 22.5 million shares of Company Common Stock at $10.00 per share, totaling $225 million.
  • Implied Valuation: The PIPE price implies a pre-money equity valuation of the Company of $120 million.
  • Redemption Rights: JATT shareholders may redeem shares for cash equal to the pro rata portion of funds in the trust account, including interest (less taxes).
  • Cash Condition: Closing is conditioned on "Available Cash" being no less than $125,000,000 after payment or accrual of certain expenses.
  • Equity Incentive Plan: Post-closing, 12% of fully-diluted shares will be reserved for an Equity Incentive Plan, with an automatic annual increase of 5%.
  • Sponsor Contribution: The Sponsor agreed to surrender 150,000 JATT Ordinary Shares for no consideration.

Material Changes and Transaction Structure

This filing represents a material change in JATT's corporate status, transitioning from a special purpose acquisition company (SPAC) to a combined operating entity with Talawar Tx Inc.

  • Merger Mechanics: Each JATT ordinary share will convert into one share of Company Common Stock following a stock split and conversion of Company convertible securities.
  • Board Composition: The post-closing board will consist of up to seven directors: one designated by the Sponsor and up to six by the Company.
  • Lock-Up Period: Key holders are subject to a 180-day lock-up period post-closing.
  • Exclusivity: Both parties are restricted from soliciting or facilitating competing acquisition proposals until closing or termination.

Guidance, Outlook, Risks, and Contingencies

Outlook and Management Commentary: Management anticipates the combined company will continue operations through the Company. The filing includes forward-looking statements regarding clinical development plans, market opportunity, and cash runway, though specific financial guidance for the combined entity is not provided in this text.

Conditions to Closing: The transaction is contingent upon:

  • Shareholder approval from both JATT and the Company.
  • SEC effectiveness of the Registration Statement (Form S-4).
  • Nasdaq listing approval.
  • Receipt of the $125 million minimum cash condition.
  • Consummation of the PIPE Financing.

Risks and Contingencies:

  • Termination: The agreement may be terminated if the transaction is not consummated by the "Outside Date," if shareholder approval is not obtained, or if a governmental authority prohibits the deal.
  • Operational Risks: Risks include the early stage of clinical development for the Company's product candidates, reliance on third-party suppliers, and regulatory approval uncertainties.
  • Market Risks: Potential volatility in the combined company's stock price and failure to maintain Nasdaq listing.

Investor Verification Checklist

  • Verify the final amount of cash in JATT's trust account to assess the redemption price per share.
  • Confirm the status of the $225 million PIPE Financing commitments and the identity of the PIPE Investors.
  • Review the upcoming Proxy Statement/Prospectus (Form S-4) for detailed financial data on Talawar Tx Inc. and the combined entity.
  • Monitor the timeline for the JATT Shareholders' Meeting and the "Outside Date" for transaction consummation.
  • Assess the clinical development stage and regulatory pathway of Talawar Tx Inc.'s product candidates as described in the investor presentation.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.